Patents by Inventor Xiaoling PUYANG

Xiaoling PUYANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrasubstituted alkene compounds and their use
    Patent number: 10851065
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 1, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20200255415
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: August 13, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux, Sudeep Prajapati, Dominic Reynolds, Morgan O'Shea, Thiwanka Samarakoon
  • SPLICEOSOME MUTATIONS AND USES THEREOF
    Publication number: 20200190593
    Abstract: Spliceosome mutations are described herein, including mutations in the PHF5A and SF3B1 subunits. This application also describes detecting the presence and/or absence of mutations in the spliceosome, as well as methods of diagnosing responsiveness to splice modulator treatment, methods of treating neoplastic disorders, and methods of monitoring or altering the treatment based on mutation status.
    Type: Application
    Filed: March 14, 2018
    Publication date: June 18, 2020
    Inventors: Markus WARMUTH, Xiaoling PUYANG, Teng TENG, Ping ZHU
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
    Publication number: 20190337921
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: November 7, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu, Lorna Helen Mitchell, Nicholas Larsen, Nathalie Rioux
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
    Publication number: 20180141913
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 24, 2018
    Applicant: EISAI R & D MANAGEMENT CO., LTD.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU, Lorna Helen MITCHELL, Nicholas LARSEN, Nathalie RIOUX, Sudeep PRAJAPATI, Dominic REYNOLDS, Morgan O'SHEA, Thiwanka SAMARAKOON
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
    Publication number: 20180127378
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: September 22, 2017
    Publication date: May 10, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU
  • Tetrasubstituted alkene compounds and their use
    Patent number: 9796683
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 24, 2017
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Mark Bock, Ming-Hong Hao, Manav Korpal, Vijay Kumar Nyavanandi, Xiaoling Puyang, Susanta Samajdar, Peter Gerard Smith, John Wang, Guo Zhu Zheng, Ping Zhu
  • TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
    Publication number: 20160347717
    Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-? protein.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Mark BOCK, Ming-Hong HAO, Manav KORPAL, Vijay Kumar NYAVANANDI, Xiaoling PUYANG, Susanta SAMAJDAR, Peter Gerard SMITH, John WANG, Guo Zhu ZHENG, Ping ZHU